Partikula Overview

  • Founded
  • 2013
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Partikula General Information


Developer of novel therapeutics designed to treat oncology and other diseases. The company's therapeutics utilize proprietary chemical engineering technologies to develop compounds that specifically and directly target mitochondria, from the outer mitochondrial membrane to the mitochondrial matrix and areas in between, enabling patients to fight off a large number of major diseases including cancer, neurodegenerative disease, cardiovascular and metabolic disease and a number of rare orphan diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 15491 South West 12th Street
  • Suite 408
  • Sunrise, FL 33326
  • United States
+1 (954) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Partikula Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Apr-2018 00.000 Completed Out of Business
4. Debt - General 30-Jun-2016 00.000 Completed Startup
3. Debt - General 20-Nov-2015 00.000 Completed Startup
2. Early Stage VC (Series A) 02-Feb-2015 $5M $5.15M Completed Startup
1. Angel (individual) 25-Mar-2014 $150K $150K Completed Startup
To view Partikula’s complete valuation and funding history, request access »

Partikula Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapeutics designed to treat oncology and other diseases. The company's therapeutics utilize propri
Sunrise, FL
00000000 00 00.000


qua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commod
0000 000000000
Nijmegen, Netherlands
00 As of 0000


esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Bala Cynwyd, PA
00 As of 0000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Partikula Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Khondrion Corporation Nijmegen, Netherlands 00 0000000000
0000000 0000000000 Formerly VC-backed Bala Cynwyd, PA 00 00000 000000000 00000
0000000000 Formerly VC-backed Cambridge, MA 00 0000 000000&0 0000
00 000000000000 Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
00000 000000000 Formerly VC-backed Boulder, CO 000 00000 000000&0 00000
You’re viewing 5 of 21 competitors. Get the full list »

Partikula Executive Team (4)

Name Title Board Seat Contact Info
Shanta Dhar Ph.D Scientific Founder
Nagesh Kolishetti Ph.D Vice President of Chemistry and Chemical Development
Marc Lippman MD Chief Medical Officer
David Kolb Chief Executive Officer, Co-Founder & Board Member
To view Partikula’s complete executive team members history, request access »

Partikula Board Members (4)

Name Representing Role Since
David Kolb Self Chief Executive Officer, Co-Founder & Board Member 000 0000
To view Partikula’s complete board members history, request access »